Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Identification of a cellularly active SIRT6 allosteric activator

Nature Chemical Biology volume 14, pages 1118–1126 (2018)Cite this article

Subjects

Matters Arising to this article was published on 01 March 2021

Abstract

SIRT6, a member of the SIRT deacetylase family, is responsible for deacetylation of histone H3 Nε-acetyl-lysines 9 (H3K9ac) and 56 (H3K56ac). As a tumor suppressor, SIRT6 has frequently been found to have low expression in various cancers. Here, we report the identification of MDL-800, a selective SIRT6 activator. MDL-800 increased the deacetylase activity of SIRT6 by up to 22-fold via binding to an allosteric site; this interaction led to a global decrease in H3K9ac and H3K56ac levels in human hepatocellular carcinoma (HCC) cells. Consequently, MDL-800 inhibited the proliferation of HCC cells via SIRT6-driven cell-cycle arrest and was effective in a tumor xenograft model. Together, these data demonstrate that pharmacological activation of SIRT6 is a potential therapeutic approach for the treatment of HCC. MDL-800 is a first-in-class small-molecule cellular SIRT6 activator that can be used to physiologically and pathologically investigate the roles of SIRT6 deacetylation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Discovery and biochemical characterization of MDL-800 and MDL-801 as activators of SIRT6 deacetylation.
Fig. 2: Cocrystal structure of MDL-801 bound to an allosteric site of SIRT6.
Fig. 3: MDL-800 induces H3K9ac and H3K56ac deacetylation and represses proliferation of HCC cells.
Fig. 4: MDL-800 arrests the cell cycle in HCC cells.
Fig. 5: MDL-800 activates SIRT6 deacetylation, thereby regulating the HCC cell cycle.
Fig. 6: MDL-800 inhibits xenograft tumor growth of HCC cells in immunocompromised mice.

Similar content being viewed by others

Data availability

Crystal structures and diffraction data have been deposited in the Protein Data Bank under accession codes PDB 5X16 (SIRT6-ADPR) and PDB 5Y2F (SIRT6–ADPR–MDL-801). All other data generated or analyzed during the study in this published article (and its supplementary information files) are available from the corresponding author on reasonable request.

References

  1. Chalkiadaki, A. & Guarente, L. The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15, 608–624 (2015).

    Article  CAS  Google Scholar 

  2. Feldman, J. L., Dittenhafer-Reed, K. E. & Denu, J. M. Sirtuin catalysis and regulation. J. Biol. Chem. 287, 42419–42427 (2012).

    Article  CAS  Google Scholar 

  3. Kugel, S. & Mostoslavsky, R. Chromatin and beyond: the multitasking roles for SIRT6. Trends Biochem. Sci. 39, 72–81 (2014).

    Article  CAS  Google Scholar 

  4. Tasselli, L., Zheng, W. & Chua, K. F. SIRT6: novel mechanisms and links to aging and disease. Trends Endocrinol. Metab. 28, 168–185 (2017).

    Article  CAS  Google Scholar 

  5. Irminger-Finger, I. Science of cancer and aging. J. Clin. Oncol. 25, 1844–1851 (2007).

    Article  CAS  Google Scholar 

  6. Sebastián, C. et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151, 1185–1199 (2012).

    Article  Google Scholar 

  7. Lin, Z. et al. USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 5, 1639–1649 (2013).

    Article  CAS  Google Scholar 

  8. Marquardt, J. U. et al. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 58, 1054–1064 (2013).

    Article  CAS  Google Scholar 

  9. Kugel, S. et al. SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell 165, 1401–1415 (2016).

    Article  CAS  Google Scholar 

  10. Van Meter, M., Gorbunova, V. & Seluanov, A. SIRT6: a promising target for cancer prevention and therapy. Adv. Exp. Med. Biol. 818, 181–196 (2014).

    Article  Google Scholar 

  11. Pan, P. W. et al. Structure and biochemical functions of SIRT6. J. Biol. Chem. 286, 14575–14587 (2011).

    Article  CAS  Google Scholar 

  12. Jiang, H. et al. SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110–113 (2013).

    Article  CAS  Google Scholar 

  13. Kawahara, T. L. et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 136, 62–74 (2009).

    Article  CAS  Google Scholar 

  14. Michishita, E. et al. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle 8, 2664–2666 (2009).

    Article  CAS  Google Scholar 

  15. Gil, R., Barth, S., Kanfi, Y. & Cohen, H. Y. SIRT6 exhibits nucleosome-dependent deacetylase activity. Nucleic Acids Res. 41, 8537–8545 (2013).

    Article  CAS  Google Scholar 

  16. Tasselli, L. et al. SIRT6 deacetylates H3K18ac at pericentric chromatin to prevent mitotic errors and cellular senescence. Nat. Struct. Mol. Biol. 23, 434–440 (2016).

    Article  CAS  Google Scholar 

  17. Ghosh, S., Liu, B., Wang, Y., Hao, Q. & Zhou, Z. Lamin A is an endogenous SIRT6 activator and promotes SIRT6-mediated DNA repair. Cell Rep. 13, 1396–1406 (2015).

    Article  CAS  Google Scholar 

  18. Feldman, J. L., Baeza, J. & Denu, J. M. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J. Biol. Chem. 288, 31350–31356 (2013).

    Article  CAS  Google Scholar 

  19. You, W. et al. Structural basis of sirtuin 6 activation by synthetic small molecules. Angew. Chem. Int. Edn Engl. 56, 1007–1011 (2017).

    Article  CAS  Google Scholar 

  20. Parenti, M. D. et al. Discovery of novel and selective SIRT6 inhibitors. J. Med. Chem. 57, 4796–4804 (2014).

    Article  CAS  Google Scholar 

  21. He, B., Hu, J., Zhang, X. & Lin, H. Thiomyristoyl peptides as cell-permeable Sirt6 inhibitors. Org. Biomol. Chem. 12, 7498–7502 (2014).

    Article  CAS  Google Scholar 

  22. Huang, W. et al. Allosite: a method for predicting allosteric sites. Bioinformatics 29, 2357–2359 (2013).

    Article  CAS  Google Scholar 

  23. Kokkonen, P. et al. Studying SIRT6 regulation using H3K56 based substrate and small molecules. Eur. J. Pharm. Sci. 63, 71–76 (2014).

    Article  CAS  Google Scholar 

  24. Pacholec, M. et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285, 8340–8351 (2010).

    Article  CAS  Google Scholar 

  25. Sinclair, D. A. & Guarente, L. Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 54, 363–380 (2014).

    Article  CAS  Google Scholar 

  26. Borra, M. T., Smith, B. C. & Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187–17195 (2005).

    Article  CAS  Google Scholar 

  27. Kaeberlein, M. et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038–17045 (2005).

    Article  CAS  Google Scholar 

  28. Mao, Z. et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 332, 1443–1446 (2011).

    Article  CAS  Google Scholar 

  29. Hu, J., He, B., Bhargava, S. & Lin, H. A fluorogenic assay for screening Sirt6 modulators. Org. Biomol. Chem. 11, 5213–5216 (2013).

    Article  CAS  Google Scholar 

  30. Tan, Y. et al. A SIRT4-like auto ADP-ribosyltransferase is essential for the environmental growth of Mycobacterium smegmatis. Acta Biochim. Biophys. Sin. (Shanghai) 48, 145–152 (2016).

    Article  CAS  Google Scholar 

  31. Dai, H., Ellis, J. L., Sinclair, D. A. & Hubbard, B. P. Synthesis and assay of SIRT1-activating compounds. Methods Enzymol. 574, 213–244 (2016).

    Article  CAS  Google Scholar 

  32. Davenport, A. M., Huber, F. M. & Hoelz, A. Structural and functional analysis of human SIRT1. J. Mol. Biol. 426, 526–541 (2014).

    Article  CAS  Google Scholar 

  33. Moniot, S., Schutkowski, M. & Steegborn, C. Crystal structure analysis of human Sirt2 and its ADP-ribose complex. J. Struct. Biol. 182, 136–143 (2013).

    Article  CAS  Google Scholar 

  34. Nguyen, G. T., Schaefer, S., Gertz, M., Weyand, M. & Steegborn, C. Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism. Acta Crystallogr. D Biol. Crystallogr 69, 1423–1432 (2013).

    Article  CAS  Google Scholar 

  35. Du, J. et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334, 806–809 (2011).

    Article  CAS  Google Scholar 

  36. Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2, 2111–2119 (2007).

    Article  CAS  Google Scholar 

  37. Min, L. et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 14, 1203–1211 (2012).

    Article  CAS  Google Scholar 

  38. Elhanati, S. et al. Reciprocal regulation between SIRT6 and miR-122 controls liver metabolism and predicts hepatocarcinoma prognosis. Cell Rep. 14, 234–242 (2016).

    Article  CAS  Google Scholar 

  39. Suter, M. A. et al. A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. FASEB J. 26, 5106–5114 (2012).

    Article  CAS  Google Scholar 

  40. Gu, Y., Turck, C. W. & Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707–710 (1993).

    Article  CAS  Google Scholar 

  41. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993).

    Article  CAS  Google Scholar 

  42. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816 (1993).

    Article  CAS  Google Scholar 

  43. Hengst, L., Dulic, V., Slingerland, J. M., Lees, E. & Reed, S. I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl Acad. Sci. USA 91, 5291–5295 (1994).

    Article  CAS  Google Scholar 

  44. Polyak, K. et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59–66 (1994).

    Article  CAS  Google Scholar 

  45. Toyoshima, H. & Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67–74 (1994).

    Article  CAS  Google Scholar 

  46. Morgan, D. O. Principles of CDK regulation. Nature 374, 131–134 (1995).

    Article  CAS  Google Scholar 

  47. Hubbard, B. P. et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–1219 (2013).

    Article  CAS  Google Scholar 

  48. Dai, H. et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat. Commun. 6, 7645 (2015).

    Article  Google Scholar 

  49. Huang, M. et al. Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer. Bioorg. Med. Chem. Lett. 26, 5172–5176 (2016).

    Article  CAS  Google Scholar 

  50. Zhao, Y. et al. Crystal structures of PI3Kα complexed with PI103 and its derivatives: new directions for inhibitors design. ACS Med. Chem. Lett. 5, 138–142 (2013).

    Article  Google Scholar 

  51. Jiang, H. et al. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat. Chem. Biol. 13, 994–1001 (2017).

    Article  CAS  Google Scholar 

  52. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We sincerely thank D. Sinclair for discussion on activator application, and C. Steegborn and A. Mai for discussion on crystallization. We thank Z.-G. Han (Key Laboratory of Systems Biomedicine, Ministry of Education, and Collaborative Innovation Center of Systems Biomedicine of Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine) for providing cell lines. This work was supported in part by grants from the National Basic Research Program of China (973 Program) (2015CB910403 to J.Z. and G.C.), the National Natural Science Foundation of China (81721004 to G.C. and J.Z.; 91753117 to J.Z.; 81322046 to J.Z.; 81302698 to S.L.; 31671459 to Y.X.; U1605221 to H.L.; and 2181001006 to H.J.), the Program for Changjiang Scholars and the Innovative Research Team of the University of the Ministry Education of China (2017 to J.Z.), the CAS Interdisciplinary Innovation Team (2017 to J.Z.), the Innovation Program of the Shanghai Municipal Education Commission (2019 to J.Z.), the State Key Laboratory of Luminescence and application (SKLA-2016-12 to Y.X.), and the Strategic Priority Research Program of the Chinese Academy of Sciences, ‘Personalized Medicines—Molecular Signature-based Drug Discovery and Development’ (XDA12040100 to H.J.).

Author information

Author notes

  1. These authors contributed equally: Zhimin Huang, Junxing Zhao, Wei Deng, Yingyi Chen, Jialin Shang.

Authors and Affiliations

  1. Key Laboratory of Cell Differentiation and Apoptosis, Ministry of Education, Department of Pathophysiology, Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China

    Zhimin Huang, Junxing Zhao, Yingyi Chen, Jialin Shang, Kun Song, Lu Zhang, Chengxiang Wang, Shaoyong Lu, Xiuyan Yang, Jianrong Xu, Qiufen Zhang, Jie Zhong, Ying Xu, Guoqiang Chen & Jian Zhang

  2. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China

    Wei Deng, Mingzhe Xiao & Y Eugene Chin

  3. Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Ministry of Education, Guizhou Medical University, Guiyang, China

    Bin He

  4. Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada

    Jinrong Min

  5. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    Hao Hu, Minjia Tan & Hualiang Jiang

  6. School of Life Sciences and Technology, Tongji University, Shanghai, China

    Xiaoxiang Sun & Zhiyong Mao

  7. Basic Clinical Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Houwen Lin & Jian Zhang

  8. Medicinal Bioinformatics Center, Shanghai JiaoTong University School of Medicine, Shanghai, China

    Jian Zhang

Authors
  1. Zhimin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junxing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yingyi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jialin Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kun Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chengxiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shaoyong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiuyan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Bin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jinrong Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hao Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Minjia Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jianrong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Qiufen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jie Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Xiaoxiang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Zhiyong Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Houwen Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Mingzhe Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Y Eugene Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Hualiang Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Ying Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Guoqiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J. Zhang conceived and supervised the project. J. Zhang and Z.H. designed the experiments. Z.H., J. Zhao,Y.C., J.S., L.Z., C.W., H.H., J.X., J. Zhong, Q.Z., X.S., and Y.X. performed the biological experiments. J. Zhang, G.C.,Y.X., Z.H., S.L., and H.L. analyzed data. Z.H. and K.S. performed the crystallography. Y.C. and X.Y. carried out synthesis, purification, and characterization of compounds. W.D., S.L., B.H., J.M., H.H., M.T., X.S., Z.M., M.X., Y.E.C., and H.J. generated key protein reagents. K.S. solved the crystal structures. J. Zhang wrote the manuscript, and all other authors contributed specific parts of the manuscript; J. Zhang, G.C., and Y.X. assume responsibility for the manuscript in its entirety.

Corresponding authors

Correspondence to Ying Xu, Guoqiang Chen or Jian Zhang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–69 and Supplementary Tables 1–20

Reporting Summary

Supplementary Note

Synthetic Procedures

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Z., Zhao, J., Deng, W. et al. Identification of a cellularly active SIRT6 allosteric activator. Nat Chem Biol 14, 1118–1126 (2018). https://doi.org/10.1038/s41589-018-0150-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41589-018-0150-0

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer